Abstract
Clonal hematopoiesis (CH) – the expansion of somatically-mutated hematopoietic cells in blood – is common in solid cancers. CH is associated with systemic inflammation that may lead to cancer, but its impact on tumor biology is underexplored. Here, we report the effects of CH on the tumor microenvironment (TME) using 1,550 treatment-naïve patient samples from the CPTAC cohort. CH was present in 18.3% of patients, with one-third of CH mutations also detectable in tumor-derived DNA from the same individual (CH-Tum), reflecting CH-mutant leukocyte infiltration. The presence of CH-Tum was associated with worse survival across cancers, particularly for glioblastoma.
Transcriptomics and proteomics revealed that CH drives inflammation in the TME in a cancer- and CH driver-specific manner, and may improve immunotherapy responses. In glioblastoma, CH associated with pronounced macrophage infiltration, inflammation, and an aggressive, mesenchymal phenotype. Our findings demonstrate that CH shapes the TME, with potential applications as a biomarker in precision oncology.
Competing Interest Statement
A.G.B. is on the scientific advisory board of TenSixteen Bio. The other authors declare no competing interests.
Funding Statement
M.M.B. was supported by a CGS-M scholarship from the Canadian Institutes for Health Research. C.V. was supported by a CGS-D scholarship from the Canadian Institutes for Health Research. A.G.B. was supported by the National Institutes of Health (Grant No. DP5-OD029586), the Burroughs Wellcome Foundation Career Award for Medical Scientists, and the Pew-Stewart Scholar for Cancer Research award. R.J.V. was supported by the Leukemia & Lymphoma Society of Canada with Canadian Institutes for Health Research, a Brain Tumour Foundation of Canada Elevation Grant, and the Princess Margaret Cancer Foundation. M.J.R. is supported by grant funding from the Canadian Institutes for Health Research (Project Grant No. 202010PJT-451137) and Ontario Institute for Cancer Research (Project No. CPTRG-056).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Health Sciences Research Ethics Board of Queen's University and the Data Access Committee of the database of Genotypes and Phenotypes/National Center for Biotechnology Information gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Supplemental data and scripts used to conduct this study will be released via Zenodo upon publication of the manuscript. Inquiries regarding data and code access should be directed to the corresponding authors.
